These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31728622)

  • 1. MnTnBuOE-2-PyP treatment protects from radioactive iodine (I-131) treatment-related side effects in thyroid cancer.
    Patel A; Kosmacek EA; Fisher KW; Goldner W; Oberley-Deegan RE
    Radiat Environ Biophys; 2020 Mar; 59(1):99-109. PubMed ID: 31728622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.
    Weitzel DH; Tovmasyan A; Ashcraft KA; Boico A; Birer SR; Roy Choudhury K; Herndon J; Rodriguiz RM; Wetsel WC; Peters KB; Spasojevic I; Batinic-Haberle I; Dewhirst MW
    Environ Mol Mutagen; 2016 Jun; 57(5):372-81. PubMed ID: 27224425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MnTnBuOE-2-PyP protects normal colorectal fibroblasts from radiation damage and simultaneously enhances radio/chemotherapeutic killing of colorectal cancer cells.
    Kosmacek EA; Chatterjee A; Tong Q; Lin C; Oberley-Deegan RE
    Oncotarget; 2016 Jun; 7(23):34532-45. PubMed ID: 27119354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+.
    Weitzel DH; Tovmasyan A; Ashcraft KA; Rajic Z; Weitner T; Liu C; Li W; Buckley AF; Prasad MR; Young KH; Rodriguiz RM; Wetsel WC; Peters KB; Spasojevic I; Herndon JE; Batinic-Haberle I; Dewhirst MW
    Mol Cancer Ther; 2015 Jan; 14(1):70-9. PubMed ID: 25319393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superoxide dismutase mimic, MnTE-2-PyP(5+) ameliorates acute and chronic proctitis following focal proton irradiation of the rat rectum.
    Archambeau JO; Tovmasyan A; Pearlstein RD; Crapo JD; Batinic-Haberle I
    Redox Biol; 2013; 1(1):599-607. PubMed ID: 24363995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.
    Ma C; Xie J; Chen Q; Wang G; Zuo S
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007956. PubMed ID: 19821441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized-controlled trial.
    Upadhyaya A; Zhou P; Meng Z; Wang P; Zhang G; Jia Q; Tan J; Li X; Hu T; Liu N; Wang S; Liu X; Wang H; Zhang C; Zhao F; Yan Z; Wang X; Zhang X; Zhang W
    Nucl Med Commun; 2017 Nov; 38(11):891-903. PubMed ID: 28806348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment.
    Torun N; Muratli A; Serim BD; Ergulen A; Altun GD
    Curr Med Imaging Rev; 2019; 15(4):395-404. PubMed ID: 31989909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust rat pulmonary radioprotection by a lipophilic Mn N-alkylpyridylporphyrin, MnTnHex-2-PyP(5+).
    Gauter-Fleckenstein B; Reboucas JS; Fleckenstein K; Tovmasyan A; Owzar K; Jiang C; Batinic-Haberle I; Vujaskovic Z
    Redox Biol; 2014; 2():400-10. PubMed ID: 24624330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Manganese-Porphyrin Superoxide Dismutase-Mimetic Widens the Therapeutic Margin in a Preclinical Head and Neck Cancer Model.
    Ashcraft KA; Boss MK; Tovmasyan A; Roy Choudhury K; Fontanella AN; Young KH; Palmer GM; Birer SR; Landon CD; Park W; Das SK; Weitner T; Sheng H; Warner DS; Brizel DM; Spasojevic I; Batinic-Haberle I; Dewhirst MW
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):892-900. PubMed ID: 26530759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin.
    Rosario PW; Calsolari MR
    Thyroid; 2013 May; 23(5):617-9. PubMed ID: 23136908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MnTE-2-PyP Treatment, or NOX4 Inhibition, Protects against Radiation-Induced Damage in Mouse Primary Prostate Fibroblasts by Inhibiting the TGF-Beta 1 Signaling Pathway.
    Chatterjee A; Kosmacek EA; Oberley-Deegan RE
    Radiat Res; 2017 Mar; 187(3):367-381. PubMed ID: 28225655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer.
    Ma C; Xie J; Jiang Z; Wang G; Zuo S
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(9):1778-85. PubMed ID: 20130857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
    Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
    J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
    Lam MG; van Isselt JW
    J Nucl Med; 2005 Dec; 46(12):2118; author reply 2118-9. PubMed ID: 16330579
    [No Abstract]   [Full Text] [Related]  

  • 16. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
    Bohuslavizki KH; Klutmann S; Bleckmann C; Brenner W; Lassmann S; Mester J; Henze E; Clausen M
    Strahlenther Onkol; 1999 Feb; 175(2):57-61. PubMed ID: 10065139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sodium-iodine symporter and the proton-pump inhibitors in - related to the side effects of- the treatment of thyroid cancer with iodine-131.
    Sfakianakis G; Sfakianaki E
    Hell J Nucl Med; 2007; 10(1):2-5. PubMed ID: 17450241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salivary gland malignancy and radioiodine therapy for thyroid cancer.
    Klubo-Gwiezdzinska J; Van Nostrand D; Burman KD; Vasko V; Chia S; Deng T; Kulkarni K; Wartofsky L
    Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment.
    Kloos RT
    Thyroid; 2009 Sep; 19(9):925-8. PubMed ID: 19731974
    [No Abstract]   [Full Text] [Related]  

  • 20. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
    Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.